Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,510 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.
Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. Mesa RA, et al. Among authors: kantarjian h. Leuk Res. 2009 Sep;33(9):1199-203. doi: 10.1016/j.leukres.2009.01.035. Epub 2009 Feb 27. Leuk Res. 2009. PMID: 19250674 Free PMC article.
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V. Giles FJ, et al. Leuk Res. 2003 Dec;27(12):1077-83. doi: 10.1016/s0145-2126(03)00118-8. Leuk Res. 2003. PMID: 12921943 Clinical Trial.
New approaches in the treatment of myelofibrosis.
Hennessy BT, Thomas DA, Giles FJ, Kantarjian H, Verstovsek S. Hennessy BT, et al. Among authors: kantarjian h. Cancer. 2005 Jan 1;103(1):32-43. doi: 10.1002/cncr.20752. Cancer. 2005. PMID: 15565565 Free article. Review.
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Giles FJ, et al. Leuk Res. 2005 Jun;29(6):649-52. doi: 10.1016/j.leukres.2004.11.013. Epub 2005 Apr 1. Leuk Res. 2005. PMID: 15863204 Clinical Trial.
2,510 results